Furthermore, docetaxel‐based chemotherapy for prostate cancer continues to face significant challenges.[36] Numerous studies have demonstrated that mitochondrial metabolism plays an indispensable role in the susceptibility of cancer cells to docetaxel.[37, 38]SFT2D2‐TBX19 plays a protective role in mitochondrial metabolism, preserving mitochondrial membrane potential and normal structures in the harsh environment induced by docetaxel, thereby promoting cell survival in prostate cancer. Here, SFT2D2 is linked to prostate carcinoma.